# Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

> **NCT02086604** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 37 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** Brentuximab vedotin
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02086604
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-18
- **Primary completion:** 2017-06-09
- **Final completion:** 2022-01-12
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02086604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02086604, "Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02086604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*